Sobuzoxane
Structural Formula Vector Image
Title: Sobuzoxane
CAS Registry Number: 98631-95-9
CAS Name: 1,2-Ethanediylbis[(2,6-dioxo-4,1-piperazinediyl)methylene]carbonic acid bis(2-methylpropyl) ester
Additional Names: 4,4¢-ethylenebis[1-(hydroxymethyl)-2,6-piperazinedione] bis(isobutyl carbonate) (ester); 4,4¢-(1,2-ethanediyl)bis(1-isobutoxycarbonyloxymethyl)-2,6-piperazinedione; 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5-dioxopiperazin-1-yl)ethane
Manufacturers' Codes: MST-16
Trademarks: Perazolin (Zenyaku Kogyo)
Molecular Formula: C22H34N4O10
Molecular Weight: 514.53
Percent Composition: C 51.35%, H 6.66%, N 10.89%, O 31.10%
Literature References: Noncleavable complex-stabilizing DNA topoisomerase II inhibitor. Prepn: J.-C. Cai, M. Takase, EP 140327; eidem, US 4650799 (1985, 1987 both to Zenyaku Kogyo); idem et al., Chem. Pharm. Bull. 37, 2976 (1989). Antitumor activity: T. Narita et al., Cancer Chemother. Pharmacol. 28, 235 (1991). Clinical evaluation in non-Hodgkin's lymphoma: R. Ohno et al., J. Natl. Cancer Inst. 84, 435 (1992); in adult T-cell leukemia-lymphoma: idem et al., Cancer 71, 2217 (1993). Acute toxicity study: T. Tokiwa et al., Iyakuhin Kenkyu 22, 435 (1991). C.A. 115, 222916k (1991).
Properties: Crystals from ethylene glycol monomethylether, mp 128-130°. Also reported as crystals from ethanol, mp 132-133° (Cai, 1989). Practically insol in water. LD50 in male, female mice, rats (mg/kg): 807, 960, 877, 567 i.p.; 400, 673, 3025, 2821 s.c.; >5 g/kg orally in all species (Tokiwa).
Melting point: mp 128-130°; mp 132-133° (Cai, 1989)
Toxicity data: LD50 in male, female mice, rats (mg/kg): 807, 960, 877, 567 i.p.; 400, 673, 3025, 2821 s.c.; >5 g/kg orally in all species (Tokiwa)
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Topoisomerase II Inhibitor.

Other Monographs:
D-Ribose-5-phosphoric AcidOrazamideAgomelatineTebufenpyrad
AlizaprideTrichostatin(s)Methylene AzurePotassium Molybdate(VI)
HomocystineDihydrocodeinone Enol AcetateWarburganalZolpidem
Liothyronineα-GlucogallinGestonorone CaproateOmalizumab
©2006-2023 DrugFuture->Chemical Index Database